About Genocea Biosciences (NASDAQ:GNCA)
Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:GNCA
- CUSIP: N/A
- Web: www.genocea.com
Capitalization:- Market Cap: $44.37 million
- Outstanding Shares: 28,624,000
Average Prices:- 50 Day Moving Avg: $3.66
- 200 Day Moving Avg: $5.12
- 52 Week Range: $1.13 - $7.29
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.40
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.67 per share
- Price / Book: 2.31
Profitability:- EBITDA: ($54,720,000.00)
- Return on Equity: -146.46%
- Return on Assets: -92.29%
Debt:- Debt-to-Equity Ratio: 0.56%
- Current Ratio: 2.97%
- Quick Ratio: 2.97%
Misc:- Average Volume: 1.24 million shs.
- Beta: 2.05
- Short Ratio: 4.44
Frequently Asked Questions for Genocea Biosciences (NASDAQ:GNCA)
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its earnings results on Wednesday, August, 9th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.08. View Genocea Biosciences' Earnings History.
When will Genocea Biosciences make its next earnings announcement?
Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?
5 equities research analysts have issued 1-year target prices for Genocea Biosciences' shares. Their predictions range from $2.50 to $18.00. On average, they anticipate Genocea Biosciences' stock price to reach $11.90 in the next twelve months. View Analyst Ratings for Genocea Biosciences.
What are analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (10/16/2017)
- 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Galectin Therapeutics (GALT), ArQule (ARQL), Tissue Regenix Group PLC (TRX), Brainstorm Cell Therapeutics (BCLI), Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Vernalis plc (VER), CytRx Corporation (CYTR), Prima BioMed Ltd (PBMD), ReNeuron Group Plc (RENE), OvaScience (OVAS), Sunesis Pharmaceuticals (SNSS), Bio-Path Holdings (BPTH), Senomyx (SNMX), Abzena PLC (ABZA), Fibrocell Science (FCSC) and Scancell Holdings Plc (SCLP).
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Katrine S. Bosley, Chairman of the Board
- William D. Clark, President, Chief Executive Officer, Director
- Jonathan M. Poole, Chief Financial Officer
- John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences
- Jessica Baker Flechtner Ph.D., Chief Scientific Officer
- Seth V. Hetherington M.D., Chief Medical Officer
- Eric S. Hoffman Ph.D., Chief Business Officer
- Ronald Harold Wilfred Cooper, Director
- George Siber M.D., Director
- Kenneth M. Bate, Independent Director
How do I buy Genocea Biosciences stock?
Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of Genocea Biosciences stock can currently be purchased for approximately $1.55.
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $11.90 (667.74% upside) |
Consensus Price Target History for Genocea Biosciences (NASDAQ:GNCA)
Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/26/2017 | Needham & Company LLC | Downgrade | Buy -> Hold | | High |  |
| 9/26/2017 | Cowen and Company | Reiterated Rating | Buy | $10.00 | High | |
| 9/25/2017 | Stifel Nicolaus | Downgrade | Buy -> Hold | $15.00 -> $2.50 | High | |
| 7/25/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $17.00 -> $18.00 | High | |
| 1/23/2017 | FBR & Co | Reiterated Rating | Outperform | | N/A | |
(Data available from 10/17/2015 forward)
Earnings History for Genocea Biosciences (NASDAQ:GNCA)Earnings History by Quarter for Genocea Biosciences (NASDAQ GNCA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/2/2017 | | ($0.51) | | | | | N/A | |
| 8/9/2017 | Q2 2017 | ($0.46) | ($0.54) | | | View | N/A | |
| 5/4/2017 | 3/31/2017 | ($0.54) | ($0.48) | | | View | Listen | |
| 2/16/2017 | Q416 | ($0.45) | ($0.56) | | | View | N/A | |
| 11/3/2016 | Q316 | ($0.44) | ($0.45) | | | View | N/A | |
| 8/4/2016 | Q216 | ($0.44) | ($0.39) | | | View | N/A | |
| 5/5/2016 | Q116 | ($0.42) | ($0.35) | | $0.24 million | View | N/A | |
| 2/11/2016 | Q415 | ($0.40) | ($0.37) | | $0.22 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.43) | ($0.37) | | $0.21 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.51) | ($0.43) | | $0.12 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.57) | ($0.64) | | $0.12 million | View | Listen | |
| 2/12/2015 | Q414 | ($0.53) | ($0.66) | | $0.31 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.43) | ($0.53) | | | View | N/A | |
| 8/6/2014 | Q2 | ($0.42) | ($0.41) | | | View | N/A | |
| 5/6/2014 | Q114 | ($0.60) | ($0.76) | $0.26 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)Current Year EPS Consensus Estimate: $-1.92 EPS
Next Year EPS Consensus Estimate: $-1.11 EPS
Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Genocea Biosciences (NASDAQ:GNCA)Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 59.25%
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/24/2017 | Jonathan Poole | CFO | Sell | 45,000 | $6.00 | $270,000.00 | |
| 11/8/2016 | Eric S. Hoffman | Insider | Buy | 7,000 | $3.49 | $24,430.00 | |
| 11/7/2016 | Jonathan Poole | CFO | Buy | 7,000 | $3.34 | $23,380.00 | |
| 11/7/2016 | William D. Clark | Insider | Buy | 2,800 | $3.49 | $9,772.00 | |
| 5/9/2016 | Jonathan Poole | CFO | Buy | 4,000 | $3.88 | $15,520.00 | |
| 12/16/2015 | William D Clark | CEO | Buy | 3,800 | $6.45 | $24,510.00 | |
| 9/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $11.35 | $25,299.15 | |
| 6/19/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 30,004 | $13.04 | $391,252.16 | |
| 6/17/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 10,618 | $13.01 | $138,140.18 | |
| 6/16/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 46,000 | $13.24 | $609,040.00 | |
| 6/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.52 | $23,449.08 | |
| 5/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.21 | $22,758.09 | |
| 4/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,283 | $11.77 | $26,870.91 | |
| 3/17/2015 | Stephen J Hoffman | Director | Buy | 700,000 | $8.25 | $5,775,000.00 | |
| 2/2/2015 | Jessica Baker Flechtner | VP | Sell | 4,699 | $8.50 | $39,941.50 | |
| 9/12/2014 | Jessica Baker Flechtner | VP | Sell | 6,435 | $12.00 | $77,220.00 | |
| 9/11/2014 | Paul Giannasca | VP | Sell | 4,071 | $11.84 | $48,200.64 | |
| 9/10/2014 | Paul Giannasca | VP | Sell | 834 | $12.35 | $10,299.90 | |
| 9/9/2014 | Paul Giannasca | VP | Sell | 2,455 | $12.43 | $30,515.65 | |
| 9/8/2014 | Paul Giannasca | VP | Sell | 2,970 | $12.80 | $38,016.00 | |
| 8/29/2014 | Paul Giannasca | VP | Sell | 6,760 | $12.50 | $84,500.00 | |
| 8/14/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 9,660 | $13.01 | $125,676.60 | |
| 8/12/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 63,794 | $13.28 | $847,184.32 | |
| 2/10/2014 | Plc Glaxosmithkline | Insider | Buy | 143,773 | $12.00 | $1,725,276.00 | |
| 2/10/2014 | Polaris Venture Management Co. | Major Shareholder | Buy | 232,820 | $12.00 | $2,793,840.00 | |
| 2/10/2014 | Stephen J Hoffman | Director | Buy | 250,931 | $12.00 | $3,011,172.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Genocea Biosciences (NASDAQ:GNCA)
Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
| Source: |
|
| Date | Headline |
|---|
 | Genocea Biosciences, Inc. (GNCA) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - October 16 at 11:20 PM |
 | Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8% - Nasdaq
www.nasdaq.com - October 7 at 11:04 PM |
 | Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
finance.yahoo.com - October 6 at 7:34 PM |
 | Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
www.zacks.com - October 5 at 8:16 AM |
| Financial Review: Eiger BioPharmaceuticals (EIGR) versus Genocea Biosciences (GNCA)
www.americanbankingnews.com - October 3 at 12:30 PM |
 | Genocea Biosciences (GNCA) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 8:31 PM |
 | Street Abandons Genocea On Strategic Shift, CEO Says Oncology Focus Wasn't Sudden
www.benzinga.com - September 27 at 5:10 PM |
| Mid-Day Market Update: Crude Oil Down Over 1%; Moleculin Biotech Shares Spike Higher
www.nasdaq.com - September 26 at 4:46 PM |
 | Genocea Biosciences (GNCA) Announces Strategic Shift to Immuno-oncology; to Explore Strategic Alternatives for GEN-003; Cut Workforce by 40%
www.streetinsider.com - September 26 at 4:46 PM |
| Axovant, Genocea Plunge into Tuesday’s 52-Week Low Club
finance.yahoo.com - September 26 at 4:46 PM |
| Genocea Biosciences, Inc. (GNCA) Downgraded by Needham & Company LLC to "Hold"
www.americanbankingnews.com - September 26 at 1:50 PM |
| Pre-Open Movers 09/26: (IZEA) (ASNA) (GHL) Higher; (AXON) (GNCA) (KDMN) Lower (more...) - StreetInsider.com
www.streetinsider.com - September 26 at 11:36 AM |
| Mid-Morning Market Update: Markets Open Higher; FactSet Research Profit Beats Views - Benzinga
www.benzinga.com - September 26 at 11:36 AM |
 | Axovant Shares Plummet On Lackluster Alzheimer's Treatment Data -Biotech Movers - TheStreet.com
www.thestreet.com - September 26 at 11:36 AM |
 | Genocea shares nearly halved on shift in drug development, layoffs - MarketWatch
www.marketwatch.com - September 26 at 11:36 AM |
| Cambridge's Genocea cuts staff and shelves lead drug in major shakeup
finance.yahoo.com - September 26 at 11:36 AM |
| Genocea shares nearly halved on shift in drug development, layoffs
finance.yahoo.com - September 26 at 11:35 AM |
| Today's Research Reports on Trending Tickers: Celldex Therapeutics and Genocea Biosciences
finance.yahoo.com - September 26 at 11:35 AM |
| Axovant Shares Plummet On Lackluster Alzheimer's Treatment Data -Biotech Movers
finance.yahoo.com - September 26 at 11:35 AM |
| Genocea Biosciences, Inc. (GNCA) Receives "Buy" Rating from Cowen and Company
www.americanbankingnews.com - September 26 at 11:18 AM |
| Stifel Nicolaus Lowers Genocea Biosciences, Inc. (GNCA) to Hold
www.americanbankingnews.com - September 25 at 9:14 PM |
| Genocea Biosciences (GNCA) Announces Strategic Shift to Immuno-oncology; to Explore Strategic Alternatives for ... - StreetInsider.com
www.streetinsider.com - September 25 at 5:38 PM |
| Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines
finance.yahoo.com - September 25 at 5:38 PM |
| Genocea Biosciences, Inc. (GNCA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 24 at 9:00 AM |
 | Genocea to Present at Cantor Fitzgerald Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 20 at 8:54 PM |
| Genocea to Present at Cantor Fitzgerald Healthcare Conference
finance.yahoo.com - September 20 at 3:53 PM |
| Head to Head Review: Genocea Biosciences (GNCA) and Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - September 6 at 12:16 AM |
| Genocea Biosciences, Inc. (GNCA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 9:12 AM |
| Brokerages Expect Genocea Biosciences, Inc. (GNCA) to Post -$0.51 Earnings Per Share
www.americanbankingnews.com - August 23 at 10:20 PM |
| Genocea Biosciences Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 7:19 PM |
| Genocea Biosciences reports 2Q loss
finance.yahoo.com - August 9 at 7:19 PM |
| Genocea Biosciences, Inc. (GNCA) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 9 at 5:32 PM |
| Analysts Anticipate Genocea Biosciences, Inc. (GNCA) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - August 5 at 2:22 PM |
| Genocea Biosciences, Inc. (NASDAQ:GNCA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 5 at 8:44 AM |
| Genocea Biosciences (GNCA) Announces Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
www.streetinsider.com - July 27 at 12:48 AM |
| Genocea Biosciences's (GNCA) Conference Call On Positive GEN-003 Phase 2b Results - Slideshow
seekingalpha.com - July 27 at 12:48 AM |
| Genocea Biosciences' (NASDAQ:GNCA) Outperform Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - July 25 at 11:10 AM |
| Genocea Biosciences, Inc. (GNCA) Receives "Overweight" Rating from Piper Jaffray Companies
www.americanbankingnews.com - July 25 at 11:10 AM |
| 18 Biggest Mid-Day Gainers For Monday | Benzinga - Benzinga
www.benzinga.com - July 24 at 8:54 PM |
| Pre-Market Most Active for Jul 24, 2017 : WBMD, NDRM, QQQ ... - Nasdaq
www.nasdaq.com - July 24 at 8:54 PM |
| Genocea Biosciences (GNCA) Announces Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes - StreetInsider.com
www.streetinsider.com - July 24 at 8:54 PM |
| Genocea Biosciences Inc (GNCA): This Analyst Turns Bullish, Sets $12 Target Price
finance.yahoo.com - July 24 at 8:54 PM |
| Cowen Sings the Praises of Genocea Biosciences Inc (GNCA) Following Positive GEN-003 Phase 2b Data
finance.yahoo.com - July 24 at 8:54 PM |
| Genocea Biosciences, Inc. (GNCA) CFO Sells $270,000.00 in Stock
www.americanbankingnews.com - July 24 at 7:29 PM |
| Genocea Biosciences, Inc. (GNCA) Upgraded to "Buy" at Needham & Company LLC
www.americanbankingnews.com - July 24 at 4:50 PM |
 | Genocea Reports 12-Month Phase 2b Data For GEN-003 In Genital Herpes
www.rttnews.com - July 24 at 8:56 AM |
| Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes
feeds.benzinga.com - July 24 at 7:38 AM |
| Genocea Biosciences, Inc. (GNCA) Expected to Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - July 14 at 11:32 AM |
| Genocea Biosciences, Inc. (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:26 AM |
| Genocea: Investment Update On ~$6 Biotech 'Busted IPO ... - Seeking Alpha
seekingalpha.com - June 1 at 3:28 AM |
Genocea Biosciences (GNCA) Chart for Tuesday, October, 17, 2017
